Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 5/20 | 0.37 |
| ▸ | FNTB | P49356 | 5/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4808846 | 0.80 | PLA2G2A (0.42) | ALDH1A1HTR6 | |
| SCHEMBL4810971 | 0.79 | PLA2G4A (0.43) | FNTAFNTBALDH1A1RAB9A | |
| SCHEMBL4813180 | 0.76 | PLA2G4A (0.34) | FNTAFNTBNR3C1PGRNR3C2 | |
| SCHEMBL4813255 | 0.73 | NR3C1 (0.38) | NR3C1PGRNR3C2AR | |
| SCHEMBL4807618 | 0.70 | ALDH1A1 (0.41) | ALDH1A1RAB9A | |
| SCHEMBL4812579 | 0.69 | PLA2G4A (0.40) | FNTAFNTBALDH1A1RAB9A | |
| SCHEMBL4812571 | 0.69 | PLA2G4A (0.43) | FNTAFNTBALDH1A1RAB9A | |
| SCHEMBL4813707 | 0.69 | PLA2G4A (0.44) | FNTAFNTBNR3C1PGRNR3C2 | |
| SCHEMBL4813225 | 0.68 | PLA2G2A (0.48) | ALDH1A1HTR6 | |
| SCHEMBL981876 | 0.67 | ALDH1A1 (0.67) | ALDH1A1BCHEHTR6RAB9APTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417063-B2 | Bicyclic heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20050228000-A1 | of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228000-A1 | of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent | F12, F11, F2 | FNTA 2730/4885FNTB 3938/4885PGGT1B 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.